1. Pink Sheet
  2. >>Market Access

Express Scripts Indication-Based Contracts For Inflammatory Drugs Begin In 2017

 
• By Cathy Kelly

Program may provide drugs with narrower labels an opportunity to gain preferred formulary status versus entrenched market leaders.

Express Scripts HQ

Indication-specific pricing may begin to reshape US reimbursement for anti-inflammatory drugs in the first half of 2017, when pharmacy benefit manager Express Scripts Holding Co. launches its new approach to contracting.

In a move away from paying for anti-inflammatory drugs as a broad category, Express Scripts will negotiate separate pricing for...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

‘Why We Would Do It Again’ – Gilead & Roche On Pioneering Global Initiative For Manufacturing Change

Gilead and Roche reflect on their experiences with a global initiative that delivered aligned regulatory decisions through joint hybrid inspections and synchronized review of post-approval changes.

Novel Alzheimer’s Drug Blarcamesine Scheduled For High-Stakes EMA Oral Explanation

 
• By Neena Brizmohun

The EMA has scheduled oral explanation meetings this week for Anavex’s blarcamesine and three other products that are nearing the end of the regulatory review cycle. These meetings usually represent the final chance for sponsors to persuade the agency that their product merits approval.

Sponsored by

The British Pharmacopoeia: Setting standards that are trusted worldwide

In this exclusive article with Peter Crowley, Secretary and Scientific Director of the BP Commission, you’ll discover how the BP is preparing for its landmark 2026 edition while strengthening its influence as a global bridge between science, regulation, and industry.